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AbstrACt
Objectives The aim of this study was to conduct a cost-
effectiveness analysis (CEA) of a high-intensity and a low-
intensity smoking cessation treatment programme (HIT 
and LIT) using long-term follow-up effectiveness data and 
to validate the cost-effectiveness results based on short-
term follow-up.
Design and outcome measures Intervention 
effectiveness was estimated in a randomised controlled 
trial as numbers of abstinent participants after 1 and 
5–8 years of follow-up. The economic evaluation was 
performed from a societal perspective using a Markov 
model by estimating future disease-related costs (in Euro 
(€) 2018) and health effects (in quality-adjusted life-years 
(QALYs)). Programmes were explicitly compared in an 
incremental analysis, and the results were presented as an 
incremental cost-effectiveness ratio.
setting The study was conducted in dental clinics in 
Sweden.
Participants 294 smokers aged 19–71 years were 
included in the study.
Interventions Behaviour therapy, coaching and 
pharmacological advice (HIT) was compared with one 
counselling session introducing a conventional self-help 
programme (LIT).
results The more costly HIT led to higher number of 
6-month continuous abstinent participants after 1 year 
and higher number of sustained abstinent participants 
after 5–8 years, which translates into larger societal costs 
avoided and health gains than LIT. The incremental cost/
QALY of HIT compared with LIT amounted to €918 and 
€3786 using short-term and long-term effectiveness, 
respectively, which is considered very cost-effective in 
Sweden.
Conclusion CEA favours the more costly HIT if decision 
makers are willing to spend at least €4000/QALY for 
tobacco cessation treatment.
IntrODuCtIOn
Smoking is likely to remain the single most 
important preventable health risk in the 
world. Despite continuously declining prev-
alence in recent decades, 1 in 10 adults in 
Sweden still smokes daily.1 Cigarette smoking 
contributes to 7.5% of the burden of disease 
in Sweden2 and was estimated to account 
for approximately €3 000 000 (31.5 billion 
Swedish kronor, SEK), including €1 000 000 
(11 billion SEK) in healthcare costs (15% 
of the national costs for health and welfare 
sector) and €1 500 000 (16 billion SEK) in 
productivity costs in year 2015.3 A decrease 
in prevalence of smoking to 5% could save 
society €1 300 000 (14.3 billion SEK) per year.
Several smoking cessation interventions, 
targeted at current smokers, are avail-
able; furthermore, evaluations so far have 
confirmed the effectiveness of the majority 
of them. Additionally, some recent studies 
emphasise that higher level of intervention 
intensity, such as additional counselling 
sessions4 and intensive support through a 
mobile application,5 resulted in the highest 
smoking cessation rates. However, due to 
increasing number of available interventions, 
decision makers have to decide which inter-
vention to implement, taking into account 
that intervention intensity increases inter-
vention costs. Relative costs and benefits of 
those interventions are important criteria, 
strengths and limitations of this study
 ► This study uses a unique possibility to compare 
cost-effectiveness analyses based on 1 and 5–8 
years of follow-up data.
 ► This economic evaluation clearly supports that more 
intensive and costly smoking cessation provision is 
cost-effective.
 ► The calculation of the intervention costs for the 
cessation programmes was based on a trial proto-
col and might be overestimated in comparison with 
routine practice.
 ► The effects of smoking cessation are probably un-
derestimated since only three disease groups are 
modelled and no effects of passive smoking are 
included.
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thus, increasing the attention on economic evaluations 
in recent years.6 7 Economic evaluations combine the 
costs and outcomes of different interventions and aim 
to determine which intervention provides the best value 
for money.8 Several studies on the cost-effectiveness of 
smoking cessation interventions comparing different 
intensity of support have been performed during the 
last few years, for example, Quit-and-Win programme,9 
comparison of standard, enhanced and intensive 
smoking cessation interventions using cell phones,10 and 
two smoking cessation approaches of different level of 
intensity for patients with cancer.11 The results suggested 
that the higher intensive interventions are preferable 
from health economics point of view, but all those eval-
uations were based on 6-month or 12-month follow-up; 
long-term follow-ups are scarce in randomised controlled 
trials (RCTs).
The effects of smoking on health occur during many 
years because current smoking influences future health 
risks; similarly, a smoking cessation today will cause smok-
ing-related health risks to tail off gradually. Thus, in 
order to estimate cost-effectiveness of smoking cessation 
interventions, a lifetime perspective is necessary, taking 
into account a variety of different costs and effects.12 
Hence, the well-established method to perform cost-ef-
fectiveness analyses (CEAs) of smoking cessation inter-
ventions involves mathematical modelling of future 
events as consequences of smoking. Systematic reviews 
of model-based economic evaluations in smoking cessa-
tion analysed different aspects, such as type of model, 
quality of the model, transferability and comparison of 
the results in different studies.12–14 Berg et al13 identified 
64 economic evaluations in smoking cessation, and the 
state-transition Markov model was the most frequently 
used. The majority of the models simulates the lifetime 
development of morbidity and mortality for smoker 
versus former smoker using relative risks for four diseases: 
chronic obstructive pulmonary disease (COPD), coro-
nary heart disease (CHD), stroke and lung cancer. The 
authors concluded that existing economic evaluations 
in smoking cessation vary in quality, resulting mainly 
from the way in which they selected their populations, 
measured costs and effects, and assessed the variability 
and generalisability of their own findings.13 One of the 
reasons of the quality issues is that all those studies are 
based on short-term follow-up (from 6 months to 1 year), 
and they have no possibilities to validate the sustainability 
of short-term effectiveness in real life; thus, they cannot 
confirm the reported cost-effectiveness results and policy 
recommendations. Moreover, the long-term assumption, 
such as relapse rate, might change the results of the 
smoking cessation cost-effectiveness.15
Our previous economic evaluation of high-intensity 
and low-intensity treatment programmes (HIT and LIT) 
for smoking cessation in a dental setting was based on 
the reported number of quitters measured as point prev-
alence abstinent (not one puff of smoke during the past 
7 days prior to 1-year follow-up). The conclusion was 
that high-intensity treatment support is the preferred 
option if the decision makers’ willingness-to-pay exceeds 
€5100 (50 000 SEK) per QALY. The base-case scenario 
of the analysis assumed a sustained abstinence for the 
quitters.16 The long-term follow-up of the programmes 
was performed 5–8 years later.17 In this study, we used a 
unique opportunity to compare CEAs of a high-intensity 
and a low-intensity smoking cessation intervention in a 
dental setting using data from short-term (1 year) and 
long-term (5–8 years) follow-up.
We set out to: (1) perform a cost-effectiveness analysis of 
a high-and a low-intensity smoking cessation programme 
in a dental setting using long-term (5–8 years) follow-up 
data and (2) compare the cost-effectiveness results with 
the previous study based on short-term (1-year) follow-up.
MethODs
summary of the smoking cessation study
In the smoking cessation intervention study,18 between 
August 2003 and February 2005, 300 adult smokers 
recruited via direct inquiry or advertising in dental or 
general healthcare were offered smoking cessation 
support performed in a dental setting. Inclusion criteria 
were daily smokers over 20 years of age, while exclu-
sion criteria were reading difficulties and problems 
with Swedish language. The participants were randomly 
assigned to two interventions; one received high-inten-
sity treatment support and one low-intensity treatment 
support.
The high-intensity smoking cessation treatment, the 
HIT programme, comprised eight individual sessions, 3.5 
hours in total over a period of 4 months, and was based on 
behaviour therapy, coaching and pharmacological advice. 
The low-intensity smoking cessation treatment, the LIT 
programme, comprised one counselling session, of up to 
45 min, introducing a conventional self-help programme 
running over 8 weeks. Both programmes were free of 
charge.
The participants answered a baseline questionnaire 
and a short-term (1 year after the planned smoking cessa-
tion date) follow-up questionnaire. Demographic charac-
teristics such as gender, age and education level were also 
collected. The effectiveness of the trial was reported else-
where.18 The analysis concluded that the more extensive 
and expensive HIT programme was more effective and 
cost-effective in terms of proportion of smokers who were 
still smoke-free after 1 year.16 18 The long-term follow-up 
was performed 5–8 years after the planned smoking cessa-
tion date. The effectiveness analysis showed that the differ-
ence in outcome between the HIT and LIT programmes 
remained relatively constant and significant in favour of 
HIT, and that abstinence at 1-year follow-up was a good 
predictor for long-term abstinence.17 All analyses were 
done using the ‘intention to treat’ approach where 
non-responders were considered as smokers. Mortality 
and morbidity data for the participants were not collected 
either by questionnaire or through the registers.
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Table 1 Characteristics of the study participants and 
programme effectiveness at 1 and 5–8 years of follow-up, by 
treatment intensity
HIT N=150 LIT N=150 P value
Study participants (n)
  Baseline measures 146 148
  12-month follow-up 
measures
132 122
  Available at long-
term follow-up
141 143





  Gender (n)
   Men 26 32 0.410
   Women 115 111
  Age at baseline (age)
   Mean (SD) 48.7 (9.6) 48.5 (11.0) 0.825
   Median 48.0 49.0
  Education (in years) 
(n)
   0–9 25 36 0.336
   10–12 60 55
   >=13 52 50
  Smoked cigarettes/
week at baseline (n)
   Mean (SD) 106 (50) 105 (40) 0.794
   Median 105 105
  Intervention 
effectiveness (n)
   1-year follow-up




   5–8 years of 
follow-up
   Sustained 
abstinence
17 7 0.030*
Relapse rate (%) 26 50 0.345
*Statistical significant differences at 0.05 level in effectiveness 
between the programmes.
HIT, High-intensity smoking cessation treatment; LIT, Low-intensity 
smoking cessation treatment.
The mean age of the participants was 49 years, and 
78% were women. Short-term follow-up (1 year) ques-
tionnaire was answered by 84% of the randomised partic-
ipants (88% for HIT vs 81% for LIT). Fourteen per cent 
(41 of the 300 participants) reported 6-month contin-
uous abstinence (not one puff of smoke during the past 
6 months); 27 (18%) individuals in HIT versus 14 (9%) 
in LIT. At long-term follow-up (5–8 years), 241 persons 
answered the questionnaire (80% for both HIT and LIT). 
Of those, 24 were sustained abstinent (17 vs 7 for HIT vs 
LIT) since the planned smoking cessation date. Relapse 
rate was 26% and 50% for participants reported 6-month 
continuous abstinence at 1-year follow-up in HIT and LIT, 
respectively, but the difference was not statistically signif-
icant. Characteristics of the study participants, as well as 
abstinence at the 1 year and at the long-term follow-up, 
are presented in table 1.
economic evaluation
Two economic evaluations were performed to obtain the 
cost-effectiveness of the more costly HIT programme in 
comparison to LIT:
1. Cost-effectiveness analysis based on the number and 
characteristics of 6-month continuous abstinent partic-
ipants according to 1-year follow-up, CEA short- term.
2. Cost-effectiveness analysis based on the number and 
characteristics of sustained abstinent participants since 
planned smoking cessation date according to 5–8 years 
of follow-up, CEA long-term.
Both analyses used the same methodology described 
below.
Economic evaluations were based on the costs to imple-
ment the programmes, the number and characteristics 
of abstinent participants and on a previously constructed 
Markov model that estimates the future health and cost 
consequences of smoking cessation. All costs were inflated 
to reflect 2018 costs according to the Swedish consumer 
price index19 and converted into 2018 Euro (€) using the 
purchasing power parity estimates with CCEMG–EPPI-
Centre Cost Converter (http:// eppi. ioe. ac. uk/ costcon-
version/ default. aspx). The CEAs followed Swedish and 
international recommendations: costs were calculated 
from a societal perspective, health effects expressed as 
quality-adjusted life-years (QALYs) and programmes 
explicitly compared in an incremental analysis (incre-
mental cost-effectiveness ratio (ICER)), with discounting 
(3% per year) and sensitivity analyses.8 20 The ICER was 
calculated by dividing the difference in total costs for 
the programmes (incremental cost) by the difference in 
the health outcomes in QALYs (incremental effect) to 
provide a ratio of extra cost per extra unit of health effect.
Intervention costs
The intervention costs were collected prospectively by 
interviewing the three dental hygienists who carried out 
the patient work, as well as the project leader and the 
project coordinator. The costs were divided into joint costs 
for the two programmes and programme-specific costs, 
and undiscounted because of the short 3-year project time. 
The joint costs were assumed, divided equally between 
the programmes, while the programme-specific costs 
included staff time for patient work, material and partic-
ipant costs. Estimation of the intervention costs has been 
described in detail previously.16 Total programme-specific 
costs amounted to €117 011; €801 per participant for 
HIT and €27 927; €189 per participant for LIT.
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Table 2 Logistic regression analysis of factors associated 
with sustained abstinence at 5–8 years of follow-up
Coefficient P value OR 95% CI
HIT 
programme
1.001 0.03* 2.72 1.09 to 6.80
Male gender −0.077 0.88 0.93 0.32 to 2.64
Age 0.005 0.82 1.00 0.96 to 1.05
Constant −3124 0.01 0.04
*Statistically significant at 0.05 level.
HIT, High-intensity smoking cessation treatment; OR, Odds Ratio.
Intervention effectiveness
For CEA short term, we used 6-month continuous absti-
nence at 1-year follow-up reported by 41 participants (14 
from HIT and 27 from LIT). For CEA long term, we used 
sustained abstinence at 5–8 years reported by 24 partici-
pants (17 from HIT and 7 from LIT), see table 1. Both 
measures were statistically significant different between 
the treatment programmes. In order to generalise the 
long-term effectiveness of our study, we performed a 
logistic regression analysis to calculate the probability of 
sustained abstinence depending on programme (HIT vs 
LIT), participant’s gender and age, see table 2.
The type of the programme (HIT vs LIT) was signifi-
cantly associated with sustained abstinence, while gender 
and age were not. The regression equation (1) demon-
strates dependence between ‘abstinence’ (1—abstinence, 
0—no abstinence) and ‘programme’ (1—HIT, 0—LIT), 
‘gender’ (1—male, 0—female) and ‘age’ (19-71):
abstinence=−3.124 +1.001*programme−0.077*gender 
+0.005*age (1)
Equation (1) allows us to calculate the probability of 
long-term abstinence, Pq, for a random participant (a 
random man/woman from a population of interest, 
smoker between 19 and 71 years old) in respective 
programme, see equation (2),
Pq=EXP (abstinence)/(1+EXP (abstinence)) (2)
Markov model
A Markov model was used to estimate health conse-
quences and societal costs of smoking cessation, further 
described in a technical report.21 The model has been 
used in similar studies in Sweden,16 22 23 and the updated 
year 2015 version was used for the current analysis.21 The 
model simulates the societal effects of quitting smoking 
on three disease groups: lung cancer, COPD and cardio-
vascular disease, including CHD and stroke. Even though 
there are other smoking-related diseases, these condi-
tions cover most of the health problems associated with 
smoking.24 The model incorporates the smoking-related 
disease risks, time-dependent remaining excess disease 
risks after quitting, the death risks for the specific and 
for unrelated diseases, as well as the societal costs of the 
diseases. All disease risks are annual age-specific and 
gender-specific excess incidence risks until death or the 
age of 95. This lifetime horizon was recommended for 
modelling of smoking cessation interventions12 because 
smoking cessation reduces smoking-related health risks 
gradually during a long period. Notably, the model does 
not contain the risk for relapse in smoking among the 
quitters. The societal costs include costs associated with 
medical treatment, community care, drugs, informal 
care and other expenditures for patients and relatives, as 
well as morbidity productivity costs. Health outcomes are 
expressed in QALYs. The number of QALYs was calcu-
lated during healthy years and years spent with a disease, 
until death or the age of 95. The model and all the param-
eters are described in detail in a technical report21 and 
online supplementary appendix 1.
Model simulations were performed according to 
gender and 5-year age groups. The simulations result in 
accumulated societal costs and health effects for lifelong 
continuing smokers and quitters at a specific age and 
gender group, respectively. The differences in societal 
costs and health effects between smoking statuses at a 
certain age are then compared outside the model, and 
constitute the avoided costs and gained health effects 
from the tobacco quitting for the specified age and 
gender group.
sensitivity analyses
Extensive sensitivity analyses on parameter values and 
methodological choices were reported in the model 
technical report.21 The model estimates were, in general, 
insensitive to changes in parameter values, except the 
most conservative multivariate analysis where the costs 
were decreased by 25%, the disease risks by 50%, the 
death risks by 10% and the risk fractions after quitting 
by 0.1. This low cost/low risk analysis led to substantial 
decreases in cost and QALY differences between quit-
ters and smokers. This sensitivity analysis was applied to 
compare costs and effects between HIT and LIT, to vali-
date the results of the CEA long-term.
To increase the generalisability of the cost-effectiveness 
results, we have also applied the probabilities of long-
term abstinence depending on programme (HIT vs LIT), 
participant’s gender and age on the modelling results. 
We estimated the avoided social costs and gained QALYs 
for a random quitter from our sample and then adjusted 
the results to the probability to quit (abstinence), calcu-
lated in (1). Cost-effectiveness was estimated for men and 
women separately.
Further, a probabilistic sensitivity analysis (PSA) was 
conducted, based on the uncertainty of the difference in 
sustained abstinent participants in the two programmes. 
The effectiveness of LIT was fixed at the 7% quit rate, 
but the HIT quit rate was sampled from the 95% CI 
(9%–22%). The PSA was performed by 10 000 runs using 
the societal costs avoided and QALYs gained for the group 
with the largest number of quitters, that is, women aged 
40–44 years. The PSA was presented as a cost-effectiveness 
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CEA short* CEA long*




gained NHp¶ NLp** N†† Costs QALYs§ NHs‡‡ NLs§§ N¶¶ Costs QALYs§
Women
  20–24 8142 0.61 1 −1 −8142 −0.61 na na na na na
  25–29 8425 0.65 1 1 8425 0.65 na na na na na
  35–39 9267 0.71 2 2 0 1 1 0
  40–44 8532 0.71 5 5 42 658 3.55 4 4 34 126 2.84
  45–49 6772 0.66 3 3 0 1 2 −1 −6772 −0.66
  50–54 5228 0.61 4 3 1 5228 0.61 1 2 −1 −5228 −0.61
  55–59 4542 0.43 4 2 2 9085 0.86 4 1 3 13 627 1.29
  60–64 3336 0.32 4 4 13 342 1.29 2 2 6671 0.64
  65–69 2023 0.33 1 −1 −2023 −0.33 na na na na na
Men
  20–24 10 430 0.74 1 1 10 430 0.74 1 1 10 430 0.74
  40–44 10 526 1.00 1 1 10 526 1.00 1 1 10 526 1.00
  45–49 11 416 0.82 1 1 0 1 1 0
  50–54 11 360 0.78 1 −1 −11 360 −0.78 na na na na na
  65–69 4084 0.46 1 1 4084 0.46 1 1 4084 0.46
Total 27 14 13 82 253 7.44 17 7 10 67 466 5.71
*Cost-effectiveness analysis.
†High-intensity smoking cessation treatment, the HIT programme.
‡Low-intensity smoking cessation treatment, the LIT programme.
§Quality-adjusted life-years.
¶NHp—number of 6-month continuous abstinent participants HIT treatment programme according to 1-year follow-up.
**NLp—number of 6-month continuous abstinent participants LIT treatment programme according to 1-year follow-up.
††Difference in numbers of 6 -month continuous abstinent participants between the treatment programmes according to 1 -year follow-up.
‡‡NHs—number of sustained abstinent participants HIT treatment according to 5–8 years of follow-up.
§§NLs number of sustained abstinent participants LIT treatment according to 5–8 years of follow-up.
¶¶Difference in number of sustained abstinent participants between the treatment programmes according to 5–8 years of follow-up.
na, not applicable.
acceptability curve, which indicates the probability that 
HIT is cost-effective versus LIT at different values of the 
willingness-to-pay for a QALY.
Patient and public involvement
This research was done without patient involvement. 
Patients were not invited to comment on the study 
design and were not consulted to develop patient rele-
vant outcomes or interpret the results. Patients were not 
invited to contribute to the writing or editing of this docu-
ment for readability or accuracy.
results
Model estimates
Model estimates for the CEA short term and CEA long 
term are presented in table 3 (societal costs and QALYs). 
The second and third columns in table 3 present the esti-
mation of avoided societal costs and QALYs gained for 
a person with respective gender and age, who became 
sustained abstinent in comparison with a continuing 
smoker. Using these data, we can estimate the difference 
in societal cost avoided and QALYs gained by multiplying 
difference in numbers of 6-month continuous abstinent 
participants between the treatment programmes (N*) or 
difference in numbers of sustained abstinent participants 
since planned smoking cessation date between the treat-
ment programmes (N**) by societal costs avoided and 
QALYs gained.
The CEA short-term indicated that HIT led to addi-
tional avoided societal costs of €82 253 and additional 
7.44 QALYs compared with LIT. The CEA long- term 
reported the difference between HIT and LIT as addi-
tional avoided societal costs of €67 466 and additional 
5.71 QALYs.
Cost-effectiveness analyses
The more costly HIT programme led to a higher number 
of 6-month continuous abstinent participants at 1-year 
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Table 4 Incremental cost-effectiveness analyses (CEAs) of the two smoking cessation treatments, HIT and LIT, for 6-month 
continuous abstinence at 1 year (CEA short term), sustained abstinence at 5–8 years of follow-up (CEA long term), and 
sensitivity analyses for CEA long term. Societal perspective, in Euro 2018
Intervention costs CEA* short CEA* long
CEA* long, 
sensitivity
CEA* long, population level, per person
Men Women
HIT† 117 011 117 011 117 011 801 801
LIT‡ 27 927 27 927 27 927 189 189
Difference in intervention costs 89 085 89 085 89 085 612 612
Difference in societal costs avoided 82 253 67 466 32 469 779 502
Incremental costs 6832 21 619 56 616 −167 110
Incremental QALYs§ 7.44 5.71 4.82 0.0664 0.0462
Incremental cost per QALY§ (ICER¶) 918 3786 11 746 <0 2391
*Cost-effectiveness analysis.
†High-intensity smoking cessation treatment, the HIT programme.
‡Low-intensity smoking cessation treatment, the LIT programme.
§Quality-adjusted life-years.
¶Incremental cost-effectiveness ratio (ICER) is calculated as incremental costs divided by incremental quality-adjusted life-years (QALYs).
Figure 1 Probabilistic sensitivity analysis on the 
effectiveness (proportion of quitters) of high-intensity 
treatment (HIT) in comparison with low-intensity treatment 
(LIT), reported as cost-effectiveness acceptability curve, 
willingness-to-pay per quality-adjusted life-year (QALY), in 
Euro 2018.
follow-up (CEA short-term), as well as higher number of 
sustained abstinent participants at 5–8 years of follow-up 
(CEA long -erm), which translates into larger costs 
avoided and health gains than LIT, see table 4. However, 
the difference in intervention costs were not fully 
balanced by the societal costs avoided, so HIT implied an 
incremental net cost of about €6832 in CEA short -term 
and €21 619 in CEA long-term, compared with LIT. HIT 
was estimated to lead to more QALYs, so the incremental 
cost per QALY of HIT compared with LIT amounted to 
€918 for CEA short-term and €3786 for CEA long-term, 
which is considered to be very cost-effective in Sweden.20 
The incremental analysis favours the more costly HIT, 
if decision makers are willing to spend at least €4000/
QALY for tobacco cessation programmes.
sensitivity analyses
The most conservative sensitivity analysis, a multivariate 
low cost/low risk analysis, was applied to CEA long-term. 
This analysis led to substantial decreases in avoided social 
costs and QALY gains for both HIT and LIT. At the same 
time, the incremental costs increased and incremental 
QALYs slightly decreased which resulted in higher incre-
mental cost of €11 746 per QALY, see table 4.
The probability of sustained abstinence varies between 
0.11 and 0.13 for men and between 0.12 and 0.14 for 
women in HIT in different ages. The corresponding 
numbers are 0.4–0.5 for men and 0.5–0.6 for women in 
LIT. The model estimates for random men and women 
were €9740/0.83 and €7165/0.66 for avoided societal 
costs/QALYs gained. Given the probability of absti-
nence, the difference in avoided societal costs per person 
between HIT and LIT was estimated as €779 for men and 
€502 for women and the correspondent difference in 
QALYs gained was 0.0664 for men and 0.0462 for women. 
The ICER was negative for men (HIT was cost saving and 
entailed positive health outcomes in comparison to LIT) 
but amounted to €2391 for women, which is close to our 
base-case analysis, see table 4.
At all values of willingness-to-pay for a QALY, including 
zero, the HIT was more cost-effective than the LIT, see 
the PSA on the HIT quit rate in figure 1.
DIsCussIOn
Main results
In this study, we performed a a cost-effectiveness anal-
ysis using the long-term follow-up data from an RCT of a 
high-intensity and a low-intensity treatment programme 
(HIT and LIT) for smoking cessation in a dental setting. 
We also validated the cost-effectiveness results of the 
previous study based on short-term follow-up.16 HIT was 
more effective in getting participants to quit smoking and 
to keep sustained abstinent, resulted in higher societal 
costs avoided and more QALYs gained among both men 
 on A









pen: first published as 10.1136/bm





7Feldman I, et al. BMJ Open 2019;9:e030934. doi:10.1136/bmjopen-2019-030934
Open access
and women, compared with LIT and thus can be consid-
ered cost-effective. The ICERs were €918 and €3786 
using short-term and long-term effectiveness, respectively, 
which are below the Swedish willingness-to-pay threshold 
of €50 000 per QALY,25 thus, indicating that the resource 
intensive HIT was cost-effective compared with the less 
resource demanding LIT. The results also confirm the 
conclusions of the previous CEA based on short-term 
follow-up data and suggest its sustainability. We would 
recommend the use of the HIT programme as a cost-ef-
fective option for smoking cessation.
Notably, the usage of both the HIT and the LIT 
programmes is not limited to dental settings and can be 
implemented in other healthcare sectors and delivered 
by trained nurses instead of dental hygienists. Since the 
salaries of registered nurses and dental hygienists are 
comparable, the conclusion of high cost-effectiveness of 
the HIT programme remains.
However, although HIT was shown to be cost-effective 
in comparison with LIT, the sensitivity analysis using the 
probability of abstinence suggested that HIT dominated 
over LIT for men (saved societal costs and generated 
more QALYs). In our sample, the majority of study partic-
ipants were women, that is why the results of the sensi-
tivity analysis for women were very close to our base-case 
analysis.
strength and limitations
The majority of CEAs on smoking cessation use 1-year 
quit rates in their models; however, it is not uncommon 
that 6-month quit rates are used.12 26 The question of 
how much we can trust the overall conclusions of such 
analyses always remains because we do not know for sure 
what happens subsequently. To our knowledge, this is 
the first study that uses a unique possibility to compare 
a previously conducted CEA based on 6-month contin-
uous abstinent participants at 1-year follow-up with a 
new evaluation, based on sustained abstinence since the 
planned smoking cessation date up to 5–8 years. We had 
the possibility to compare the results based on 6-month 
continuous abstinence (when some time-dependent 
excess disease risks remained for the first years after quit-
ting) and sustained abstinence for 5–8 years (when the 
smoking-related excess disease risks had been reduced). 
A higher proportion of sustained abstinent participants 
in HIT compared with LIT contributed to a low ICER for 
the long-term CEA.
The effects of smoking cessation are certainly underes-
timated in the model estimates since only three disease 
groups including lung cancer are modelled and no effects 
of passive smoking are included, but smoking is causally 
related to at least 15 other types of cancer. In addition, 
quitting smoking reduced the rate of incidence diabetes 
to that of non-smokers after 5 years in women and after 
10 years in men.27 The model does not include the health 
problems related to passive smoking, such as risk of CHDs 
in offspring28 and increase in risk for breast cancer.29 That 
makes our estimations more conservative with respect to 
cost savings and QALYs, although these three diseases 
groups do account for over 80% of morbidity (and 
mortality) associated with smoking and are frequently 
used in similar studies.15 30 Another limitation is that the 
model does not include the relapse rate among the quit-
ters. This tends to overestimate the health and cost conse-
quences of the tobacco quitting based on short-term 
outcomes because the relapse rate is presumably higher 
among the short-term quitters. On the other hand, the 
relapse rate might be negligibly low among individuals 
that quit smoking 5–8 years ago and thus not important 
for the modelling results. Additionally, as mentioned in 
our previous study,16 the Markov model indicates consid-
erably lower smoking-related disease risks for women 
reported by large epidemiological studies (see model 
technical report for details),21 and thus lower cost savings 
and health gains from tobacco cessation for women than 
for men. Finally, the intervention costs for the RCT study 
calculation was based on the trial protocol and might 
be overestimated in comparison with routine practice; 
however, in the ICER, those extra costs were divided 
equally between the programmes, and thus disregarded.
Comparison with other studies
We could not find any CEAs based on more than 1-year 
follow-up, and therefore we compared our results with 
other studies estimating cost-effectiveness of interven-
tions with different level of intensity using 6-month 
or 12-month follow-up. Thus, a CEA of high-intensity 
multiple contest and low-intensity enhanced contest of 
a Quit-and-Win programme reported that high intensity 
Quit-and-Win leads to an average gain of 0.03 QALYs 
and was cost saving, in comparison with lower intensity.9 
Another study presented a CEA of three smoking cessa-
tion interventions with different intensity levels: Standard 
Care (SC) (brief advice to quit, nicotine replacement 
therapy and self-help written materials), Enhanced Care 
(EC) (SC plus cell phone-delivered messaging) and 
Intensive Care (IC) (EC plus cell phone-delivered coun-
selling).10 The overall conclusion was that the higher 
intensive intervention (IC) was the most cost-effective 
strategy both for men and women, which is in line with 
our results. Additionally, a CEA of two smoking cessation 
approaches for patients with cancer was presented in a 
study from Canada.11 The basic programme consisted of 
screening for tobacco use, advice and referral, whereas 
the best practice programme included a basic programme 
and pharmacological therapy, counselling and follow-up. 
The ICER of the best practice programme compared with 
the basic programme was $3367 per QALY gained for men 
and $2050 per QALY gained for women. These results are 
very similar to our findings. In our previous study,16 based 
on the same RCT and 1-year follow-up, a higher ICER of 
€9900/QALY and €5500/QALY was calculated for point 
prevalence and continuous abstinence, respectively, but 
the overall conclusion confirmed the cost-effectiveness of 
HIT at a willingness-to-pay of €10 000.
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In conclusion, the more costly HIT smoking cessation 
programme is an economically attractive option when 
compared with the LIT programme over a broad range 
of assumptions, using shot-term and long-term outcomes. 
CEA favours the more costly HIT if decision makers are 
willing to spend at least €4000/QALY for tobacco cessation 
treatment. These findings can support and guide imple-
mentation of smoking cessation programmes.
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